. . . . . "ACE inhibitors" . . . "Candesartan" . . . "systolic dysfunction" . . . "left ventricular hypertrophy" . . . "congestive heart failure" . . . "coronary artery disease" . . . "diabetic nephropathy" . . . "hypertension" . . . "myocardial infarction" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "2022-10-13T13:05:17.366019"^^ . . " Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors. May be used as first line agent to delay progression of diabetic nephropathy. May also be used to treat uncomplicated hypertension and left ventricular hypertrophy." . "2.3.0" . "RSA" . "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB" . "MAhQy/hOxC+dyVxLapqtUFLGrrxQcvpWbu04syi3CV3HE0GhGj1nkk5sHTmUwMdeNsVQq4/5+h9q7jx8N8f40A+wL4IKpIlgxzoKLEIVlJq+xQz20CfUnRbiBpFISVdH+OUu3Urf0IsdRD+3CJ/V64fcofP54e77bE57Si7E+qq+/IJjem9TbBR1Ln8dUExJictUpTvPuJGk6/unvpQBjP7jqWG/7DaqidqGMm1ao732lhrdSNfXQfOVTNicqINyMpP9DroRLYGNDfvanszFQLxu4kOA8V+tRLIk2+QCzUkPFls89ySYlpl2PD5shzq0bh3dQzTgd+ic9XxEcuXJSw==" . . "2022-10-13T13:05:17.366019"^^ . .